Meeting Coverage > > IGCS Video Pearls– Domenica Lorusso information the value of modern-day radiotherapy in this program
by Greg Laub, Director, Video, MedPage Today December 12, 2023
Incorporating checkpoint blockade with pembrolizumab (Keytruda) into basic concurrent chemoradiotherapy plus brachytherapy considerably enhanced progression-free survival in cervical cancer and revealed an early pattern towards much better general survival (OS) also, according to trial information provided at the International Gynecologic Cancer Society yearly conference.
In this MedPage Today video, lead author Domenica Lorusso, MD, PhD, of the Catholic University of Rome, talks about why she thinks the KEYNOTE-A18 results might show to be practice-changing and why the quality of the radiotherapy matters in this mix
Following is a records of her remarks:
This is an alleviative setting. We are trying to find general survival, however likewise progression-free survival in an alleviative setting. It’s crucial to examine likewise, since there will be for sure in KEYNOTE-A18 clients that will get immunotherapy after development since [with] KEYNOTE-826 [pembrolizumab] has actually been authorized all over the world. We have to take into factor to consider immunotherapy after development. We need to consider tisotumab vedotin [Tivdak]